Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.

Bahl, A; Oudard, S; Tombal, Bertrand; Ozgüroglu, M; Hansen, S; Kocak, I; Gravis, G; Devin, J; Shen, L; de Bono, J S; Sartor, A O; for the TROPIC Investigators

doi:10.1093/annonc/mdt194

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.

Bahl, A

;

Oudard, S

;

Tombal, Bertrand

;

Ozgüroglu, M

;

for the TROPIC Investigators

;et.al.

(2013) Annals of Oncology — Vol. 24, n° 9, p. 2402-2408 (2013)

Files

Bahl-2013-Impactofcabazitaxelon2-year.pdf

Restricted Access
Adobe PDF
224.08 KB

Request a copy

Details

Authors

Bahl, A
Author
Oudard, S
Author
Tombal, BertrandUCLouvain
Author
Ozgüroglu, M
Author
for the TROPIC Investigators
Author

Abstract

Cabazitaxel prolongs OS at 2 years versus mitoxantrone and has low rates of peripheral neuropathy. Palliation benefits of cabazitaxel were comparable to those of mitoxantrone. The study was registered with www.ClinicalTrials.gov (NCT00417079).

Affiliations

Citations

APA
Chicago
FWB

Bahl, A., Oudard, S., Tombal, B., Ozgüroglu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., Sartor, A. O., & for the TROPIC Investigators. (2013). Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Annals of Oncology, 24(9), 2402-2408. https://doi.org/10.1093/annonc/mdt194 (Original work published 2013)